PT Merck Tbk (ISX:MERK) Research & Development: Rp112 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:MERK PT Merck Tbk ISX:MERK
84 GF Score
Price Rp3,760.00
GF Value Rp4,944.61
Valuation Modestly Undervalued
View Full Analysis

What is PT Merck Tbk Research & Development?

PT Merck Tbk ISX:MERK +0.53% 84 Research & Development is Rp112 Mil as of Mar. 2026. GuruFocus rates ISX:MERK with a GF Score™ of 84/100 and a GF Value™ of Rp4,944.61 (Modestly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. PT Merck Tbk's Research & Development for the three months ended in Mar. 2026 was Rp0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was Rp112 Mil.

PT Merck Tbk  (ISX:MERK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Merck Tbk Research & Development Related Terms

PT Merck Tbk Research & Development Historical Data

* Premium members only.

The historical data trend for PT Merck Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Merck Tbk Research & Development Chart

PT Merck Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 166.75 288.16 541.77 347.59 0.00

PT Merck Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 112.45 0.00 0.00
ISX:MERK
84GF Score
PT Merck Tbk ISX:MERK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Merck Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp112 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Rp112 Mil mean?
PT Merck Tbk (ISX:MERK) has a Research & Development of Rp112 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PT Merck Tbk and its competitors.
Is PT Merck Tbk's Research & Development too high?
PT Merck Tbk's current Research & Development is Rp112 Mil. Overall, PT Merck Tbk has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's Research & Development compare to ZTS and UTHR?
PT Merck Tbk's Research & Development of Rp112 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Merck Tbk and its competitors. PT Merck Tbk's current Research & Development is Rp112 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,944.61, compared to a current price of Rp3,760.00 — trading 24% below its estimated fair value. The current Research & Development is Rp112 Mil. PT Merck Tbk's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current Research & Development is Rp112 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?

Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued. The current stock price of Rp3,760.00 is trading 24% below its estimated GF Value™ of Rp4,944.61. GuruFocus considers PT Merck Tbk to be Modestly Undervalued.

Key valuation signals for ISX:MERK:

  • Research & Development: Rp112 Mil
  • GF Value™: Rp4,944.61 vs. price of Rp3,760.00 (24% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Merck Tbk Business Description

Address Jalan T.B. Simatupang No. 8, Pasar Rebo, Jakarta Timur, IDN, 13760
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
84GF Score

Get the complete analysis for ISX:MERK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp3,760.00
Price
Rp4,944.61
GF Value